查詢結果分析
相關文獻
- 某醫學中心萬古黴素使用合理性之回溯性評估
- 萬古黴素
- 中部某醫院vancomycin抗藥性腸球菌之分子生物學研究報告
- Antimicrobial Susceptibilities of Clinical Isolates of Vancomycin-Resistant Enterococci in Taiwan
- Invasive Infections due to Vancomycin-resistant Enterococci in Adult Patients
- Vancomycin血中藥物濃度監測探討
- 腸球菌的抗藥性和治療
- Characterization of the First Clinical Isolate of Vancomycin-Resistant Enterococcus Faecalis, AH803, in Taiwan
- 萬古黴素抗藥性腸球菌
- Collagen as Drug Carrier for Deep Sternal Wound Infection after Open Heart Surgery
頁籤選單縮合
題 名 | 某醫學中心萬古黴素使用合理性之回溯性評估=An Evaluation of Vancomycin Usage at a Medical Center |
---|---|
作 者 | 黃莉英; 張藏能; 王春玉; 沈淑惠; 黃建賢; 李淑華; | 書刊名 | 院內感染控制雜誌 |
卷 期 | 12:3 2002.06[民91.06] |
頁 次 | 頁144-151 |
分類號 | 418.281 |
關鍵詞 | 萬古黴素; 合理性使用; Vancomycin; Appropriateness use; |
語 文 | 中文(Chinese) |
中文摘要 | 萬古黴素 (vancomycin) 對於 mothicillin-resistant Staphylococcus aureus(MRSA) 引起的感染而言,經常是首選治療的藥物。為了避免萬古黴系的濫用,及確保病人接受合理及有效的藥物治療,本研究之目的在評估某醫學中心萬古黴素的使用情形。收集 2000 年 10 月至 12 月所有使用萬古黴素的住院病患共 48 人,作回溯性的分析。使用萬古黴素的患者其年齡分佈 60 歲以上者佔了 56.7%(34入);在 48 人中, 16人 (33.3%)為菌血症,其中 11人 (22.9%)為 MRSA,另 5人(10.4%)為 S. epider-midis。 40 人符合萬古黴素的合理性使用。在臨床監測指標中,79.1%的病患在使用萬古黴素前,已做血清中肌酸酐 (Serum creatinine;Scr)的監測,而用藥過程中,病人接受血清中肌酸酐監測比率為 64.6%;在治療結果方面, 43.8%(21人)在接受萬古黴素治療後,白血球的數目恢復正常的範圍內。另外,5人(10.4%) 在使用萬古黴素後腎功能變差,懷疑可能為藥物所引起的腎毒性併發症。(感控雜誌2002;12:144-51) |
英文摘要 | Vancomycin has been used with increasing frequency for the treatment of infections caused by the methicillin-resistant Staphylococcus aureus (MRSA). We conducted a retrospective study of the appropriateness of the vancomycin usage on 48 patients hospitalized between October and December, 2000, at a medical center in Taipei, Thirty-three of them had MRSA infections of blood (11), respiratory tract (7), wound (8), urinary tract (2), and multiple sites (5); 5 had methicillin-resistant S. epidertnidis (MRSE) infections. Of the ten others, 2 had culture-negative infective endocarditis with history of allergy to beta-lactams; 3 had no growth in cultures; and 5 had growth of gram-negatives and were considered to have the drug used inappropriately. Average duration of the medication was 12.8-ir 12.3 days, with median of 10 days (range: 1- 48 days). Only 7 of them had the vancomycin serum level tested. Of the 43 patients who had good reasons to use the drug, 10 (32.6%) had negative conversion of the positive culture; and 24 (55.8%) required additional antibiotics. Twenty-one patients (48.8%) had normalization of the WBC after the therapy; 14 (32.6%) continued to have abnormal leukocyte count; 7 died; and I discharged in terminal condition. During the therapy, macular rashes developed in 4 (9.3%), drug fever in 2 (4.7%), and a rise in serum creatinine over 0.5 mg/dL in 5 (10.4%). (Nosocom Infect Control d 2002:12:144-51) |
本系統中英文摘要資訊取自各篇刊載內容。